Binding of an antagonistic monoclonal antibody to an intact and fragmented EGF-receptor polypeptide
about
P1343
Immunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent CancersMatuzumab Binding to EGFR Prevents the Conformational Rearrangement Required for DimerizationGlycosylation-induced conformational modification positively regulates receptor-receptor association: a study with an aberrant epidermal growth factor receptor (EGFRvIII/DeltaEGFR) expressed in cancer cells.EGFR-targeted granzyme B expressed in NK cells enhances natural cytotoxicity and mediates specific killing of tumor cells.Population pharmacokinetic data analysis of three phase I studies of matuzumab, a humanised anti-EGFR monoclonal antibody in clinical cancer developmentStrategies to adapt adenoviral vectors for targeted delivery.Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiologyThe human EGF receptor as a target for cancer therapy: six new rat mAbs against the receptor on the breast carcinoma MDA-MB 468.Tumor necrosis factor alpha induces the expression of transforming growth factor alpha and the epidermal growth factor receptor in human pancreatic cancer cells.Novel therapeutics in adult malignant brain gliomas.Matrix-independent survival of human keratinocytes through an EGF receptor/MAPK-kinase-dependent pathwayRegulation of Bcl-xL expression in human keratinocytes by cell-substratum adhesion and the epidermal growth factor receptor.Inhibition of tyrosine kinase activity of the epidermal growth factor (EGF) receptor by a truncated receptor form that binds to EGF: role for interreceptor interaction in kinase regulation.Cytokine-mediated enhancement of epidermal growth factor receptor expression provides an immunological approach to the therapy of pancreatic cancer.Direct identification of residues of the epidermal growth factor receptor in close proximity to the amino terminus of bound epidermal growth factorInteraction of antibodies with ErbB receptor extracellular regions.Identification of a truncated form of the nerve growth factor receptor.Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges.Targeting the epidermal growth factor receptor in solid tumor malignancies.Recombinant IgE antibody engineering to target EGFR.Phosphorylation of tyrosine 992, 1068, and 1086 is required for conformational change of the human epidermal growth factor receptor c-terminal tail.Recent progress in protein-protein interaction study for EGFR-targeted therapeutics.In vitro effects and ex vivo binding of an EGFR-specific immunotoxin on rhabdomyosarcoma cells.Targeting of a hydrophilic photosensitizer by use of internalizing monoclonal antibodies: A new possibility for use in photodynamic therapy.Comparison of aluminium (III) phthalocyanine tetrasulfonate- and meta-tetrahydroxyphenylchlorin-monoclonal antibody conjugates for their efficacy in photodynamic therapy in vitro.A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth.A novel mechanism for anti-EGFR antibody action involves chemokine-mediated leukocyte infiltration.Noncontiguous regions in the extracellular domain of EGF receptor define ligand-binding specificity.Induction of a T- and B-cell response against a unique amino acid sequence of the mouse IgG2A hinge region in a MAb-treated patient.Epidermal growth factor receptor-dependent control of keratinocyte survival and Bcl-xL expression through a MEK-dependent pathway.Novel EGFR-specific immunotoxins based on panitumumab and cetuximab show in vitro and ex vivo activity against different tumor entities.On-line immunoanalysis of monoclonal antibodies during a continuous culture of hybridoma cells.A conformation-specific anti-peptide antibody to the beta-type platelet-derived growth factor receptor also recognizes the activated epidermal growth factor receptor.Semi-synthetic vNAR libraries screened against therapeutic antibodies primarily deliver anti-idiotypic binders.EGF stimulates the processing and export of a secreted form of EGF receptor.Antitumor effect of MAb EMD 55900 depends on EGF-R expression and histopathology.Anti-epidermal growth factor receptor-antibody therapy for treatment of breast cancer.Improved gene transfer efficiency to primary and established human pancreatic carcinoma target cells via epidermal growth factor receptor and integrin-targeted adenoviral vectors.Metastasis-associated protein (MTA)1 enhances migration, invasion, and anchorage-independent survival of immortalized human keratinocytes.Biosynthesis and turnover of a 34-kDa protein growth factor in human cytotrophoblasts
P2860
Q26751473-EBA19868-F20A-4109-9A68-6184057CB64CQ27650259-E0D29911-4108-4CE4-905D-DBC254A8E2E3Q27863678-3F2A9273-A954-4EC6-AEFD-33053F141921Q31115054-7E999538-9F3B-422B-9381-13234851C24EQ31148686-3919F390-DBDE-475F-8A7D-1A60AF5EA4E7Q33833388-60DE67E8-0343-4E14-9CD0-BE3381FE2491Q34435505-4344CA2A-ED98-4BEF-B005-58A24CBCCAC3Q35975667-07FC16F4-26FA-4762-9AA4-164D8327F46EQ36078622-B60A93A0-ECBA-4AB7-BF1B-1EE8088F8D52Q36187046-2F7AC7E6-A30F-4E67-BD4C-999F17C0E5B9Q36285442-CEF13023-D167-45F8-9AAD-B14EE82F8040Q36765120-A3689264-83E5-4F90-BF7E-8D4E9F9E5C45Q36766355-A1A357F1-0702-4030-9E87-8F8A956AA173Q36827083-4F79546E-CDA0-4685-94D1-2A5249942E59Q37165330-8682535E-1DA5-4838-B0A7-A9929A907084Q37320814-C42171B1-EA7F-4B6D-A9C4-7405F229A3E2Q37481293-59ACFF05-4786-4F8A-8AA0-DA42C3895883Q37485865-4F15FEB3-5589-446E-8DBC-BEED399AEA9EQ37990044-02E5492C-21C2-48E1-9816-26D58DD4C949Q38016758-9DCE42A4-6DB0-4C98-A7CB-948F89B41F62Q38609896-C168FCF3-C1C6-4900-9058-06E701D74A7FQ38899428-BEF46CAE-3A0A-4BEF-921C-8D1760A0AC04Q38936986-B102F142-3C93-4730-906C-F619C4701FFEQ39120026-B4465537-3E64-4D52-A959-2C360139A1C0Q39122815-7E8A83E2-2FE4-43E4-B6DD-1B4C6742DBA0Q39552974-1CC0630D-AE0A-4DB3-8AD2-35A2EF72D6B3Q39885205-EE4DD294-2761-4842-B01B-4681D236EF7EQ40642471-1DEFEBE2-D9DC-4B57-A44A-E8F2334DBF1BQ40644388-AE3A9E25-0E9B-4490-A3D2-7D90687D2F89Q40839619-AE7AE72F-970B-4F88-83E7-02EA83101B85Q41033340-60B8F13C-296D-46C4-B7EE-AA0F457314A1Q41111079-F60F3E62-B8DC-4EA8-80FB-1FA3ABF534CAQ41351129-ABB8E364-B2B9-40F1-9C72-81AD6C5FBB22Q41548612-C3F75EB1-2DE0-4CCB-8625-375E09DA1DB5Q41718227-1CC5AD22-FCD9-43DC-A975-81E104884F77Q42430947-BAE87F45-18C0-48DB-AC72-683CBABC1DF5Q44124416-03E6A6F1-BB9F-4B3A-985E-23E4D96C4BB5Q45878386-E801E022-E1B5-4A85-9FFB-93761ACD7C20Q55035784-E03A597B-8B22-40FB-B9EF-EDE230213FE3Q56794786-087A59C7-AC9F-46F2-9F0C-D7E81C8AEA96
P2860
Binding of an antagonistic monoclonal antibody to an intact and fragmented EGF-receptor polypeptide
description
1987 nî lūn-bûn
@nan
1987 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1987 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1987年の論文
@ja
1987年学术文章
@wuu
1987年学术文章
@zh-cn
1987年学术文章
@zh-hans
1987年学术文章
@zh-my
1987年学术文章
@zh-sg
1987年學術文章
@yue
name
Binding of an antagonistic mon ...... ented EGF-receptor polypeptide
@ast
Binding of an antagonistic mon ...... ented EGF-receptor polypeptide
@en
Binding of an antagonistic mon ...... ented EGF-receptor polypeptide
@nl
type
label
Binding of an antagonistic mon ...... ented EGF-receptor polypeptide
@ast
Binding of an antagonistic mon ...... ented EGF-receptor polypeptide
@en
Binding of an antagonistic mon ...... ented EGF-receptor polypeptide
@nl
prefLabel
Binding of an antagonistic mon ...... ented EGF-receptor polypeptide
@ast
Binding of an antagonistic mon ...... ented EGF-receptor polypeptide
@en
Binding of an antagonistic mon ...... ented EGF-receptor polypeptide
@nl
P2093
P3181
P1476
Binding of an antagonistic mon ...... ented EGF-receptor polypeptide
@en
P2093
P304
P3181
P356
10.1016/0003-9861(87)90062-2
P407
P4510
P577
1987-02-01T00:00:00Z